New erythromycin derivatives enhance β-lactam antibiotics against methicillin-resistant Staphylococcus aureus
Z. Li, M. He, X. Dong, H. Lin, H. Ge, S. Shen, J. Li, R.D. Ye and D. Chen
Article first published online: 14 JAN 2015 | DOI: 10.1111/lam.12378
Significance and Impact of the Study: This study is the first report on the synergy of anti-MRSA between new erythromycin derivatives and β-lactam antibiotics in vitro. The results show that although the erythromycin derivatives have poor anti-MRSA effects alone, they possess high synergism with oxacillin against MRSA ATCC43300 and clinically isolated MRSA. These novel compounds can significantly reduce the dosage of β-lactam antibiotics against MRSA, while this synergistic effect is different from the combination of β-lactams and β-lactamase inhibitors. The research may provide a new choice for the treatment of infection caused by MRSA and be useful to the research and development of new combination of medicines.